Bio-Rad Laboratories Class A
515 hedge funds and large institutions have $10.7B invested in Bio-Rad Laboratories Class A in 2022 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 189 increasing their positions, 191 reducing their positions, and 77 closing their positions.
0.27% more ownership
Funds ownership: 77.08% → 77.36% (+0.27%)
1% less repeat investments, than reductions
Existing positions increased: 189 | Existing positions reduced: 191
3% less funds holding
Funds holding: 533 → 515 (-18)
12% less first-time investments, than exits
New positions opened: 68 | Existing positions closed: 77
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
25% less capital invested
Capital invested by funds: $14.3B → $10.7B (-$3.59B)
37% less call options, than puts
Call options by funds: $58.3M | Put options by funds: $92M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$158M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$80.8M |
| 3 |
Renaissance Technologies
New York
|
+$79.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$76.9M |
| 5 |
NC
Nitorum Capital
New York
|
+$66.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$602M |
| 2 |
IIP
Intermede Investment Partners
London,
United Kingdom
|
-$171M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$33.9M |
| 4 |
APG Asset Management
Amsterdam,
Netherlands
|
-$30.4M |
| 5 |
Morgan Stanley
New York
|
-$29.5M |
BIO Hedge Fund Activity: Q1 2022 in Review
515 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q1 2022, worth a combined $10.7B — down 25% from $14.3B a quarter earlier.
Sellers outnumbered buyers: 77 funds closed out of BIO and 68 opened new positions — a net loss of 9 holders — while 191 trimmed existing stakes and 189 added.
The largest buyer was Millennium Management, adding an estimated $158M. The largest seller was Fidelity Investments, cutting an estimated $602M.
- 515 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q1 2022, down from 533 in Q4 2021.
- Funds reported $10.7B of Bio-Rad Laboratories Class A stock for Q1 2022, down 25% quarter-over-quarter.
- 68 funds opened new Bio-Rad Laboratories Class A positions in Q1 2022 and 77 closed out, a net change of -9 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q1 2022 was Millennium Management, an estimated $158M added.
- The largest Bio-Rad Laboratories Class A seller in Q1 2022 was Fidelity Investments, an estimated $602M sold.
Based on aggregated 13F filings for Q1 2022.